scholarly journals New Option for Metastatic Colorectal Cancer: Oxaliplatin and Novel Oral S-1 Combination Chemotherapy

10.5772/27417 ◽  
2011 ◽  
Author(s):  
Dae Young
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy

Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients

2008 ◽  
Vol 63 (3) ◽  
pp. 501-507 ◽  
Author(s):  
Koji Okabayashi ◽  
Hirotoshi Hasegawa ◽  
Yoshiyuki Ishii ◽  
Takashi Endo ◽  
Hiroki Ochiai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy ◽  
Japanese Patients

Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial

2020 ◽  
Vol 25 (7) ◽  
pp. 1285-1290
Author(s):  
Yoshihiko Nakamoto ◽  
Masafumi Noda ◽  
Ryuichi Mikami ◽  
Yukihiko Tokunaga ◽  
Tatsuo Okumoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Phase Ii ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Sequential Combination

Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 561-561
Author(s):  
S. Yuki ◽  
K. Shitara ◽  
M. Yoshida ◽  
D. Takahari ◽  
S. Utsunomiya ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy ◽  
Response Rate ◽  
Standard Dose ◽  
Objective Response ◽  
Progression Free Survival ◽  
Wild Type ◽  
Standard Regimen ◽  
Free Survival

561 Background: Weekly cetuximab and irinotecan is a standard regimen in heavily pretreated patients with metastatic colorectal cancer (MCRC). The aim of this study was to prospectively evaluate the efficacy of combination chemotherapy with biweekly cetuximab and irinotecan in patients with pretreated MCRC harboring wild-type KRAS. Methods: Patients with wild- type KRAS MCRC that had progressed after chemotherapy with irinotecan, oxaliplatin, and fluoropyrimidine were included in this study. Cetuximab was administered at 500 mg/m2 biweekly with irinotecan. The primary endpoint was response rate. The secondary endpoints included adverse events, progression-free survival, and overall survival. The pharmacokinetics of cetuximab was also evaluated in five patients. Results: From May, 2009 to February, 2010, a total of 31 patients were enrolled from five institutions. One patient was not eligible. Among the 30 assessable patients, ECOG PS was 0 in 12, 1 in 16, and 2 in two patients. The objective response rate was 30.0% (95% confidence interval [CI], 14.7-49.4), and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95%CI, 61.4-92.3). The median progression-free survival was 5.3 months (95%CI, 3.4-7.3). Grade 3 skin toxicity was observed in 3 patients (10%), and treatment related death due to pneumonia occurred in one patient. Conclusions: The efficacy data are similar to those of standard dose of cetuximab plus irinotecan. Combination chemotherapy with biweekly cetuximab and irinotecan is effective for pretreated metastatic wild-type KRAS MCRC. No significant financial relationships to disclose.

Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3551-3551
Author(s):  
Dominik Paul Modest ◽  
Ingrid Ricard ◽  
Volker Heinemann ◽  
Susanna Hegewisch-Becker ◽  
Wolff H. Schmiegel ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy ◽  
Braf Mutations ◽  
Exon 2 ◽  
Kras Exon

scholarly journals The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy

2012 ◽  
Vol 23 (4) ◽  
pp. 948-954 ◽  
Author(s):  
C. Suzuki ◽  
L. Blomqvist ◽  
A. Sundin ◽  
H. Jacobsson ◽  
P. Byström ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy ◽  
Tumor Size ◽  
Initial Change

Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy

1999 ◽  
Vol 35 ◽  
pp. S73
Author(s):  
T.M. Loeffler ◽  
C. Droege ◽  
B.H.M. Lenfers ◽  
T.U. Hausamen
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Folinic Acid ◽  
Combination Chemotherapy ◽  
Dose Dense
Sign in / Sign up

Export Citation Format

Share Document